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ABSTRACT
HIV-1 maturation inhibitors are a novel class of antiretroviral compounds that consist of two structurally distinct chemical
classes: betulinic acid derivatives and the pyridone-based compound PF-46396. It is currently believed that both classes act by
similar modes of action to generate aberrant noninfectious particles via inhibition of CA-SP1 cleavage during Gag proteolytic
processing. In this study, we utilized a series of novel analogues with decreasing similarity to PF-46396 to determine the chemi-
cal groups within PF-46396 that contribute to antiviral activity, Gag binding, and the relationship between these essential prop-
erties. A spectrum of antiviral activity (active, intermediate, and inactive) was observed across the analogue series with respect to
CA-SP1 cleavage and HIV-1 (NL4-3) replication kinetics in Jurkat T cells. We demonstrate that selected inactive analogues are
incorporated into wild-type (WT) immature particles and that one inactive analogue is capable of interfering with PF-46396 in-
hibition of CA-SP1 cleavage. Mutations that confer PF-46396 resistance can impose a defective phenotype on HIV-1 that can be
rescued in a compound-dependent manner. Some inactive analogues retained the capacity to rescue PF-46396-dependent mu-
tants (SP1-A3V, SP1-A3T, and CA-P157S), implying that they can also interact with mutant Gag. The structure-activity relation-
ships observed in this study demonstrate that (i) the tert-butyl group is essential for antiviral activity but is not an absolute re-
quirement for Gag binding, (ii) the trifluoromethyl group is optimal but not essential for antiviral activity, and (iii) the
2-aminoindan group is important for antiviral activity and Gag binding but is not essential, as its replacement is tolerated.
IMPORTANCE
Combinations of antiretroviral drugs successfully treat HIV/AIDS patients; however, drug resistance problemsmake the devel-
opment of newmechanistic drug classes an ongoing priority. HIV-1 maturation inhibitors are novel as they target the Gag pro-
tein, specifically by inhibiting CA-SP1 proteolytic cleavage. The lack of high-resolution structural information of the CA-SP1
target in Gag has hindered our understanding of the inhibitor-binding pocket andmaturation inhibitor mode of action. There-
fore, we utilized analogues of the maturation inhibitor PF-46396 as chemical tools to determine the chemical components of
PF-46396 that contribute to antiviral activity and Gag binding and the relationship between these essential properties. This is the
first study to report structure-activity relationships of the maturation inhibitor PF-46396. PF-46396 is chemically distinct from
betulinic acid-derived maturation inhibitors; therefore, our data provide a foundation of knowledge that will aid our under-
standing of how structurally distinct maturation inhibitors act by similar modes of action.
HIV-1 infectivity is dependent upon proteolytic maturation,which occurs concomitantly with immature virus particle as-
sembly and release from the host cell plasma membrane. Imma-
tureHIV-1 particles are assembled viamultimerization of the Gag
(Pr55Gag) protein. Gag multimerization also drives the incorpo-
ration of the Gag-Pol polyprotein that contains the viral enzy-
matic proteins protease (PR), reverse transcriptase (RT), and in-
tegrase (IN). Key regions ofGag that drivemultimerization are the
capsid (CA) C-terminal domain (CTD) and the adjoining SP1
region. More specifically, within the CA CTD, residuesW184 and
M185 in helix 9 are important for Gag dimerization (1, 2); while
the major homology region (MHR) is required for the formation
and stabilization of the Gag lattice (1–4), the CA CTD tail and the
adjoining SP1 region are important for higher-order Gag-Gag
multimerization (5–9). During proteolytic maturation, Gag and
Gag-Pol are cleaved into their individual proteins by the virus-
encoded PR. Pol is cleaved into PR, RT, and IN, andGag is cleaved
into four proteins, MA (matrix), CA, NC (nucleocapsid), and p6,
and two spacer peptides, SP1 and SP2. Gag cleavage is kinetically
controlled by a differential rate of processing at each of the five
cleavage sites and hence follows a sequential cascade (10–15). An
initial cleavage event creates anN-terminalMA-CA-SP1 fragment
and a C-terminal NC-SP2-p6 fragment. These fragments are sub-
sequently cleaved at theMA-CA and the SP2-p6 sites and finally at
the NC-SP2 and CA-SP1 sites. Upon the completion of the Gag
proteolytic processing cascade, the virus particle undergoes a
morphological rearrangement that results in a mature infectious
particle that contains the conical capsid. HIV-1 assembly, release,
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and proteolytic maturation have been extensively reviewed
(16–20).
Correct proteolytic processing of Gag is essential for the for-
mation of infectiousHIV-1 particles, asmutations that disrupt the
cleavage of individual sites or alter the order in which sites are
cleaved result in aberrant particles that have significantly reduced
infectivity (13, 15, 21–26). The vital role of proteolyticmaturation
in the production of infectious HIV-1 particles has made it an
attractive target for therapeutic intervention (20, 27). Protease
inhibitors (PIs) have been developed, which target HIV-1 PR en-
zyme activity, preventing all cleavage events in Gag and Gag-Pol
and resulting in noninfectious immature virus particles. PIs have
been highly successful and are routinely used in the clinic to treat
HIV-1-infected patients as a component of HAART (highly active
antiretroviral therapy). HAART is a combination of three to four
different antiretroviral drugs and successfully reduces morbidity
andmortality inHIV-1-infected patients (28–31). Combinational
therapy is used due to the ease with whichHIV-1 can acquire drug
resistance; however, despite the tangible success of this approach,
drug resistance remains an important ongoing issue that makes
the identification and development of new mechanistic drug
classes ongoing priorities, particularly in the face of the continued
lack of an effective vaccine or cure (32).
HIV-1 maturation inhibitors are members of one such new
mechanistic class of antiretroviral compounds that are under in-
vestigation (17, 32). Maturation inhibitors differ from PIs as they
target theGag substrate of PR rather than the enzymatic activity of
PR. The principalmechanismof action ofmaturation inhibitors is
the inhibition of SP1 cleavage from the C terminus of CA during
the Gag proteolytic processing cascade (4, 33–35). The conse-
quence of blocking CA-SP1 cleavage is the production of nonin-
fectious particles with an aberrant morphology (4, 15, 33). This
aberrantmorphology is associated with the incomplete formation
of the protein shell with a hexagonal honeycombCA lattice, which
is reminiscent of the Gag lattice in immature virus particles (36,
37). The structural organization of maturation inhibitor-treated
particles suggests that, in addition to preventing CA-SP1 cleavage,
maturation inhibitors also stabilize the immature Gag lattice and
that both of these modes of action may contribute to the genera-
tion of noninfectious particles and, hence, the inhibitory activity
of maturation inhibitors (36, 37).
Two structurally distinct chemical classes ofmaturation inhib-
itors have been identified: (i) betulinic acid derivatives, including
the first-in-class compoundbevirimat (BVM), also known as 3-O-
(3=,3=-dimethylsuccinyl)betulinic acid (DSB) or PA-457 (33, 34,
38, 39), and (ii) a pyridone-based compound, PF-46396 ({1-[2-
(4-tert-butylphenyl)-2-(2,3-dihydro-1H-inden-2-ylamion)ethyl]-
3-(trifluoromethyl)pyridin-2(1H)-one}) (35). Despite the struc-
tural differences between these two compound classes, they both
appear to act via the same general mode of action, as described
above. PF-46396 has not been developed clinically, but BVM pro-
gressed to phase II clinical trials. In these trials, BVM significantly
reduced the viral load in approximately half of the patients treated
(40, 41).However, problemswere encountered in the treatment of
the remaining patients due to preexisting SP1polymorphisms that
conferred intrinsic resistance to BVM, resulting in patients failing
to respond (41–45). Development of BVM was discontinued in
2010; however, potent BVM analogues that are active against
HIV-1 strains that harbor SP1 polymorphisms are being devel-
oped (46–48). It is expected that these new maturation inhibitors
will enable further clinical testing of this novel class of antiretro-
viral compounds (17).
Future development of maturation inhibitors will also benefit
from further elucidation of (i) the undefined inhibitor-binding
pocket in assembled Gag, (ii) the precise mode of action and
mechanism(s) of inhibitor resistance, and (iii) how chemically
distinct betulinic acid-derived and pyridone-based compounds
apparently act via similar modes of action. Traditionally, these
issues could be resolved by obtaining atomic-resolution structures
of a compound bound to its target. Unfortunately, this informa-
tion is not currently available for maturation inhibitors, primarily
because the CA-SP1 region of Gag is disordered, as determined by
X-ray crystallographic studies (1, 49), nor is it fully resolved by
cryo-electron microscopy (EM)/tomography, which generates
subnanometer-resolution structures of the Gag lattice in imma-
ture particles (50). However, it is broadly accepted from the avail-
able evidence that this region of Gag adopts a helical structure that
exists as a hollow six-helix bundle that is situated directly below
the hexagonal honeycomb CA lattice in immature particles (6, 21,
50–55). Importantly, virus assembly is required for BVM activity;
hence, it is hypothesized that the unknown inhibitor-binding
pocket is formed upon Gag-Gag multimerization during virus
assembly (33, 56, 57). Inhibitor binding studies have shown that
BVMdirectly interacts with two regions of Gag: the CA-SP1 junc-
tion and the upstreamMHR inCA (58). Todate, no direct binding
studies with PF-46396 have been reported; however, competition
assays with PF-46396 and BVM demonstrated that the two com-
pounds exhibit mutually antagonistic behaviors, suggesting that
these two compounds at least partially share the same binding
pocket (4).
Genetic studies determining acquisition of inhibitor resistance
in vitro have also been used to elucidate the maturation inhibitor
mode of action and the residues involved in inhibitor binding. In
these studies, resistance to BVM is attained by single-amino-acid
mutations that map exclusively to the CA-SP1 junction of Gag
(33, 34, 39, 59, 60). The preexisting SP1 polymorphisms that con-
fer intrinsic BVM resistance (41–45) have also been mapped to
this junction. In contrast, PF-46396 resistance is not conferred
by the key SP1 polymorphism V7A (4). Instead, acquired resis-
tance to PF-46396 has been mapped to mutations in the CA-
SP1 junction; many of these mutations are the same as those
acquired in the presence of BVM (4). Additionally, PF-46396
resistance was also acquired at CA residue 201 and the MHR that
lies upstream of the CA-SP1 junction (4, 35). In the majority of
cases, mutations conferring resistance to BVM were found to im-
pair the ability of the inhibitor to bind to immature virus particles
(61). Thismechanismof resistance is not consistent with the BVM
resistance mutation SP1-A3V, which imposes a replication defect
on the virus that is rescued in a compound-dependent manner,
indicating that the compound is still capable of binding to Gag in
this mutant context (39). PF-46396 is also capable of rescuing
SP1-A3V in a compound-dependent manner, along with other
inhibitor resistance mutations that map to the CA-SP1 junction
(4). Interestingly, the PF-46396 resistance mutations that map to
the MHR also impose a severe replication defect on the virus,
which is rescued in a compound-dependent manner by PF-46396
but not BVM (4). Rescue of these MHR mutants can also be
achieved by second-site compensatorymutations that map to SP1
(4). A recent study of one of these second-site compensatory mu-
tations, SP1-T8I, demonstrated that this mutation impairs CA-
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SP1 processing and stabilizes the immatureGag lattice, and hence,
the phenotype of this mutant mimics the effect of maturation
inhibitors (62). The evidence generated to date suggests that there
is structural and functional cross talk between the CA MHR and
SP1 and that BVM and PF-46396 interact differentially with a
putative pocket that involves both of these regions of Gag (4).
In this study, we further investigate themode of action/binding
of PF-46396, which, since its discovery in 2009 (35), has been the
subject of only two studies (4, 37). Our approach takes advantage
of the synthetic tractability of this compound to generate a series
of analogues that were utilized as chemical tools to further under-
stand themode of action of PF-46396. Our intention here was not
to increase compound potency and/or drug-like properties, as
Pfizer, which discovered PF-46396, has already embarked on such
a campaign and reported a correlation between increased potency
and lipophilicity, which is undesirable for drug development (35).
Although Pfizer stated that its analogue series exhibits a definable
structure-activity relationship, no details have been reported (35).
Here we chemically synthesized a series of 15 analogues with de-
creasing similarity to the parental PF-46396 compound and re-
port their structure-activity relationships with respect to antiviral
activity, Gag binding, and the correlation between these two im-
portant properties.
MATERIALS AND METHODS
Cell culture, plasmids, and transfections.HeLa cells (ATCC)weremain-
tained inDulbeccomodified Eaglemedium supplementedwith 10% (vol/
vol) fetal bovine serum (FBS). The Jurkat T cell line (ATCC) was main-
tained in RPMI 1640 supplemented with 10% (vol/vol) FBS. All media
were supplemented with 2 mM L-glutamine. Plasmids used were the in-
fectious HIV-1 molecular clone pNL4-3 (63); two derivatives with point
mutations at SP1 residue 3 (SP1-A3V and SP1-A3T) (39); four derivatives
with point mutations in CA at residues 156 (CA-G165E), 157 (CA-
P157S), 160 (CA-P160L), and 225 (CA-G225D) (kind gift from Eric
Freed, NIH, USA) (4); and two protease-defective derivatives, pNL4-3/
PR with the active-site mutation PR-D25N, which contains either wild-
type (WT)Gag or the SP1-A3Vmutation (64). PlasmidDNAwas purified
with a plasmid purification maxiprep kit (Qiagen) and adjusted to 1 g/
l. HeLa cells were transfected by using Lipofectamine 2000 (Invitrogen)
according to the manufacturer’s instructions, and Jurkat T cells were
transfected by using DEAE-dextran (65).
Maturation inhibitors and cellular cytotoxicity assay. The HIV-1
maturation inhibitor PF-46396 and an inactive analogue, PF-4348182,
were provided through the Pfizer Compound Transfer Program. A series
of experimental PF-46396 analogues were synthesized (see Fig. S1 in the
supplemental material for details of the synthetic route used and com-
pound analysis). All compounds were dissolved in dimethyl sulfoxide
(DMSO) and used at the concentrations indicated. Inhibitor cytotoxicity
assays were performed by using the CellTiter 96 AQueous One Solution
Cell Proliferation [3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxy-
phenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS)] assay (Promega)
with both the HeLa and Jurkat T cell lines.
Replication kinetics. Jurkat T cells were transfected with pNL4-3WT
and mutant derivatives. Compounds (5 M) were added at the time of
transfection and were maintained throughout the course of the experi-
ment. The transfected Jurkat T cells were split everyMonday,Wednesday,
and Friday; supernatants were collected at each time point; and viral rep-
lication was monitored by RT activity as previously described (66). Cell
pellets were harvested on the days of peak RT activity, and genomic DNA
was extracted by using awhole-bloodDNAextraction kit (Qiagen).Main-
tenance of SP1 or CA mutations and acquisition of additional mutations
were investigated by amplification of the entire Gag-PR coding region
using forward and reverse primersNL516F (5=-TGCCCGTCTGTTGTG
TGACTC-3=) and NL2897R (5=-AAA ATA TGCATCGCCCACAT-3=),
respectively. The resultant 2.3-kb PCR product was purified by using a
QIAquick PCR purification kit (Qiagen) and then sequenced by using
primers NL1410F (5=-GGA AGC TGC AGA ATG GGA TA-3=) and
NL1754F (5=-TGG TCC AAA ATG CGA ACC-3=).
Radioimmunoprecipitation analysis. Radioimmunoprecipitation
analysis was used to examine Gag proteolytic processing and virus release
efficiency. Compounds were used throughout the experiment at 5 Mor
the indicated concentrations and were prepared immediately prior to use
and mixed by vortexing. Metabolic labeling of HeLa cells, preparation of
cell and virus lysates, and immunoprecipitation methods were described
in detail previously (67). In brief, HeLa cells were transfected with the
pNL4-3WTor amutant derivative. TransfectedHeLa cells were starved in
Cys-Met-free medium for 30min and thenmetabolically radiolabeled for
2 h with [35S]Cys-Met Promix (PerkinElmer). Ultracentrifugation was
used to pellet virions. Cell and virus lysates were immunoprecipitated
with pooled immunoglobulin fromHIV-1-infected patients (HIV-Ig) ob-
tained through the NIH AIDS Research and Reference Reagent Program,
Division of AIDS, NIAID. The radioimmunoprecipitated proteins were
separated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and exposed to X-ray film and a phosphorimager plate
(Fuji), and the bands were quantified by using a Fujifilm FLA-5000 phos-
phorimager and ImageStudio software (Li-Cor).
Mass spectrometric analysis to quantify compound incorporation
into immature virus particles. Immature particles were generated by
transfecting HeLa cells with pNL4-3/PR or pNL4-3/PR/SP1-A3V and
culturing the cells in the presence of the compound at 5 M. Virus-
containing supernatants were harvested, clarified by centrifugation for 5
min at 1,200 rpm at 4°C, and then filtered by using a 0.45-m filter disc.
Particles were concentrated by ultracentrifugation through a 20% sucrose
cushion at 100,000  g for 2 h at 4°C. Pelleted virus particles were sus-
pended in STE buffer (100mMNaCl, 50mMTris-HCl, 1mMEDTA [pH
7.4]) and purified by equilibrium ultracentrifugation on a linear 30 to
70% sucrose gradient for 16 h at 36,000 rpm at 4°C in a Beckman SW55
rotor. Fractions of 0.5 ml were harvested and assayed for the presence of
Gag via SDS-PAGE andWestern blotting, followed by immunodetection
with HIV-Ig and goat anti-human IRDye680RD-conjugated secondary
antibody (Li-Cor). Peak fractions were pooled, and total Gag was quanti-
fied by using the same SDS-PAGE/Western blot/immunodetection pro-
cedure and scanned by using an Odyssey CLx instrument (Li-Cor). To
quantify the levels of the compound present, pooled fractions were spiked
with 100 pmol of StA-MAT-5 as an internal standard prior to being ex-
tracted with a 3:1 (vol/vol) solution of chloroform and methanol. The
chloroform-rich phase containing the extracted analogues and the inter-
nal standard was transferred to a new glass tube and dried under a flow of
nitrogen gas. Samples were suspended in 15 l of a 1:2 (vol/vol) solution
of chloroform-methanol and 5 l of acetonitrile-isopropanol-water (6:
7:2) and delivered using a NanoMate instrument (Advion) to an AB Sciex
4000 quadrupole ion-trap mass spectrometry instrument with a nano-
electrospray source, using nitrogen as the collision gas. A multiple-reac-
tionmonitoring (MRM) approachwas utilized to quantify the compound
bound to the isolated virus particles. The MRMmass transition (Table 1)
for each of the compounds was determined in the positive-ion mode
TABLE 1 MRM transitionsa
Metabolite
MRM transition
(m/z)
Collision
energy (V)
Declustering
potential (V)
Response
factor
StA-MAT-5 (IS) 338¡147 50 45 50.63
PF-46396 455¡322 40 40 58.69
PF-4348182 438¡305 25 35 45.85
StA-MAT-7 338¡180 50 40 72.66
StA-MAT-23 413¡260 40 40 94.88
StA-MAT-30 435¡322 45 40 112.90
a IS, internal standard.
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(entrance potential [EP] of 8 eV, collision cell exit potential [CXP] of 12
eV, interface temperature of 30°C, gas pressure of 0.5 lb/in2, tip voltage of
1.25 to 1.5 kV, and dwell time of 500 ms), and spectra were acquired for 2
min. All MRMdata were normalized to the internal standard before stan-
dard curves were generated (0.1 to 500 pmol) for each of the compounds,
allowing its own response factor to be determined. Samples were analyzed
in the same manner, allowing quantification of the compounds extracted
from the isolated virus particles.
RESULTS
Synthesis of a novel analogue series based on the HIV-1 matu-
ration inhibitor PF-46396. In order to further interrogate the
mode of action of known HIV-1 maturation inhibitors, we syn-
thesized an initial analogue series based on the second-in-class
pyridone-based compoundPF-46396 (Fig. 1). The analogue series
can be broadly divided into 3 groups, group 1, group 2, and group
3, which have decreasing similarity to the parental compound
PF-46396. In group 1, the 2-aminoindan group is unchanged, but
modifications are introduced to the trifluoromethyl group on the
pyridone core (StA-MAT-17 and -21) or the tert-butyl group on
the phenyl ring (StA-MAT-22, -23, -24, -25, and -26). In group 2,
the 2-aminoindan group was replaced with a benzylamine frag-
ment with various substituents (StA-MAT-18, -27, -28, -29, and
-30), and group 3 represents precursor ketoneswithout the 2-ami-
noindan group (StA-MAT-5, -6, and -7).
The novel PF-46396 analogues were synthesized by using an
efficient 3-step sequence from commercially available starting
materials (see Fig. S1 and associated experimental procedures in
the supplemental material). All analogues were shown to be of the
required structure and purity level by using a range of analytical
methods (see Fig. S1 in the supplemental material for details).
Compound cytotoxicity was measured by using an MTS assay to
monitor cell viability via cellular redox potential. PF-46396, PF-
4348182, and the analogue series at concentrations of10Mdid
not cause cytotoxicity after 24 h in the HeLa cell line or Jurkat T
FIG 1 Chemical structures of BVM, PF-46396, and analogues. Controls are the maturation inhibitors BVM, PF-46396, and PF-4348182, which is an inactive
analogue with a replacement of the tert-butyl group on the phenyl ring with a 2-pyridyl group and a replacement of the trifluoromethyl group on the pyridone
corewith amethoxy group. The test analogue series consisted of three groups. Group 1 analogues had a replacement of the trifluoromethyl group on the pyridone
core with a chloro group (StA-MAT-17) or no substituent (StA-MAT-21) or a replacement of the tert-butyl group on the phenyl ring with no substituent
(StA-MAT-22), a methyl group (StA-MAT-23), a methoxy group (StA-MAT-24), a trifluoromethyl group (StA-MAT-25), or a chloro group (StA-MAT-26).
Group 2 analogues had the 2-aminoindan group replaced with a benzylamine fragment with no substituent on the benzyl ring (StA-MAT-18) or with a
replacement at position 4 of the benzyl ring with a methoxy group (StA-MAT-27), a trifluoromethoxy group (StA-MAT-28), or a bromo group (StA-MAT-29)
or had the 2-aminoindan group replaced with an (aminomethyl)cyclohexane group (StA-MAT-30). Group 3 contains analogues with no 2-aminoindan group
(StA-MAT-5) or no 2-aminoindan group and a replacement of the tert-butyl group on the phenyl ring with a methoxy group (StA-MAT-6) or a chloro group
(StA-MAT-7).
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cells (data not shown). All subsequent experiments were per-
formed with compounds at a final concentration of 5M, and no
significant toxicity was observed. The only exception was incuba-
tion with 5MStA-MAT-18, -24, and -30 for7 days in Jurkat T
cells, where some cellular cytotoxicity was observed by micros-
copy; however, HIV-1 replication was not inhibited.
Effect of the PF-46396 analogue series on inhibition of CA-
SP1 processing and HIV-1 replication. The principal antiviral
mode of action ofHIV-1maturation inhibitors is the inhibition of
CA-SP1 proteolytic processing, the consequence of which is the
accumulation of an uncleaved CA-SP1 intermediate and the for-
mation of aberrant noninfectious virus particles (4, 33–35, 38).
We tested analogue activity by examining the inhibition of CA-
SP1 proteolytic cleavage using a previously described biochemical
assay to quantitate CA-SP1 levels in virus particles (39). The assay
was performed by using the wild-type pNL4-3 HIV-1 infectious
molecular clone and either the required volume of a compound
stock solution in DMSO to give a final compound concentration
of 5 M or an equivalent volume of DMSO (Fig. 2). Consistent
with previously reported results (4, 35), treatment with PF-46396
resulted in a significant accumulation of the uncleaved CA-SP1
intermediate in virus particles. A spectrum of CA-SP1 processing-
inhibitory activity was observed across the analogue series, and
analogues were categorized as being either active (50% CA-
SP1), intermediate (30 to 50% CA-SP1), or inactive (30% CA-
SP1). These designations are derived from previous studies corre-
lating variable levels of uncleaved CA-SP1 and effects on HIV-1
infectivity (26, 43). Only one analogue, StA-MAT-17 from group
1, was designated active; however, its activity was reduced com-
pared to that of PF-46396. Two analogues, StA-MAT-21 and StA-
MAT-18 from group 1 and group 2, respectively, exhibited inter-
mediate inhibition of CA-SP1 proteolytic processing. All the other
analogues were designated inactive. A subset of these inactive an-
alogues (PF-4348182 and StA-MAT-24, -25, -26, and -30) gener-
ated a small amount of the uncleaved CA-SP1 intermediate, sug-
gesting that these analogues retain a very low level of inhibitory
activity but that this is unlikely to impact virus infectivity.
To correlate the biochemical data with the effect of the ana-
logues on HIV-1 infectivity, we evaluated virus replication kinet-
ics in the Jurkat T cell line. The WT pNL4-3 HIV-1 infectious
FIG 2 Inhibition of CA-SP1 processing by the PF-46396 analogue series as determined by a quantitative CA-SP1 processing assay. HeLa cells were transfected
with pNL4-3/WT and culturedwith 5Mcompound or an equivalent volume ofDMSO.Cells weremetabolically labeled for 2 hwith [35S]Met-Cys, and released
virions were pelleted by ultracentrifugation. (A) Virus lysates were immunoprecipitated with HIV-Ig, and processing of CA-SP1 to CA was analyzed by
SDS-PAGE and fluorography. (B) Phosphorimager analysis was used to quantify the percentage of CA-SP1 relative to total CA-SP1 plus CA in pelleted virus
samples. Mean values from independent experiments are presented (n 3), and error bars indicate standard deviations.
PF-46396 Structure-Activity Relationships
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molecular clone was transfected into Jurkat T cells and passaged
over time either in the absence of the compound or in the presence
of a final compound concentration of 5 M (Fig. 3). In the ab-
sence of the compound, WT NL4-3 replication peaked at 12 days
posttransfection. As expected, the activematuration inhibitor PF-
46396 completely inhibited virus replication (up to 26 days in
culture, when the experiment was terminated). HIV-1 replication
was not inhibited by any of the analogues except StA-MAT-17,
-21, and -18. Like PA-46396, StA-MAT-17 completely suppressed
virus replication for the duration of the experiment. The analogue
StA-MAT-21 inhibited virus replication until 24 days posttrans-
fection, when virus replication began to emerge. Genomic DNA
was extracted from virus-infected cells, the Gag and PR coding
regions were PCR amplified, and the CA CTD plus SP1 were se-
quenced to demonstrate that the virus had acquired the previously
identified PF-46396 resistance mutation SP1-A3V (4). The delay
in virus replication and acquisition of a resistance mutation dem-
onstrates that StA-MAT-21 imposes an inhibitory activity on
HIV-1 replication despite this analogue imposing intermediate
(38%) inhibition of CA-SP1 cleavage. The other analogue, StA-
MAT-18, that exhibited intermediate (31%) inhibition of CA-SP1
cleavage also resulted in delayed replication kinetics. Replication
was slow to begin and plateaued at between 16 and 21 days post-
transfection. Sequencing revealed that this virus did not acquire
FIG 3 Effects of PF-46393 analogues onWT pNL4-3 HIV-1 replication kinetics in Jurkat T cells. Jurkat T cells were transfected with WT pNL4-3 and cultured
with 5Mcompound or an equivalent volume of DMSO. Cells were split at regular intervals, and supernatants were reserved at each time point for RT analysis.
The dashed line represents the peak day (day 12) of WT NL4-3 replication when cultured in DMSO.
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any mutations in the CA CTD or SP1. Therefore, StA-MAT-18
causes delayedHIV-1 replication, but it does not impose sufficient
inhibitory pressure on the virus such that the acquisition of a
resistance mutation is a requirement for virus replication. A re-
peat of this replication experiment, which used a subset of ana-
logues, verified the observations described above.
Overall, the results obtained in the biochemical and replication
data sets are in agreement. All analogues except StA-MAT-17, -21,
and -18 are inactive. PF-4348182, the negative control provided by
Pfizer, is included within the inactive set of analogues. Only two
analogues, StA-MAT-17 and -21, have antiviral activity, which
imposes sufficient pressure on the virus to result in the acquisition
of a resistance mutation. StA-MAT-18 has intermediate antiviral
activity but does not impose sufficient pressure on the virus to
result in the acquisition of resistance mutations. The spectrum of
activities across the analogue series allows us to gain insights into
structure-activity relationships for this class of HIV-1 maturation
inhibitors with respect to the inhibition of CA-SP1 proteolytic
processing.
Rescue of SP1 residue 3mutants by PF-46396 analogues.Re-
sistance to maturation inhibitors can impose a defective pheno-
type on HIV-1 that can be rescued in a compound-dependent
manner (4, 39). This compound dependence implies that the
mechanism of resistance is not via the prevention of compound
binding, but instead, the mutation causes a conformational
change in Gag that permits PR access to the CA-SP1 cleavage site
even when the compound is bound. In order to gain further in-
sights into the mode of action of PF-46396, we determined if our
panel of analogues retained the ability to rescue mutant HIV-1
and, hence, interact with Gag, at least in the context of the mutant
tested. In the first instance, we tested the SP1 residue 3 mutants
SP1-A3V and SP1-A3T. BVMwas previously shown to rescue the
replication of the SP1-A3V mutant but not the more severe SP1-
A3T mutant (39), whereas PF-46396 rescues the replication of
both SP1-A3V and SP1-A3T (4).
We first confirmed that the SP1 residue 3 mutations conferred
resistance to the analogue series by testing a selection of analogues
with various degrees of inhibitory activity (Fig. 4). The ability of
the analogue to rescue defective SP1-A3V and SP1-A3T replica-
tion was evaluated in the Jurkat T cell line (Fig. 5). Due to low
yields of StA-MAT-25 and -26 during synthesis, these two ana-
logues were not included in the experiment presented in Fig. 5.
However, StA-MAT-25 was included in a confirmatory repeat ex-
periment that utilized a subset of analogues (Table 2). The repli-
cation capacity of the SP1 residue 3 mutants was consistent with
previously reported results (4, 39). In the absence of the com-
pound, replication of the SP1-A3Vmutant was delayed by 12 days
compared to the WT virus, and the emergence of replication co-
incided with the acquisition of a second-site mutation (SP1-T8I)
in combinationwith the SP1-A3Vmutation (Fig. 5) or a loss of the
SP1-A3V mutation and reversion to the WT sequence (Table 2).
In contrast, the SP1-A3T mutant displayed no detectable replica-
tion over the course of the experiment (Fig. 5 and Table 2).
As expected, PF-46396 completely reversed the replication de-
fect imposed by both the SP1-A3V and SP1-A3T mutations. In-
terestingly, PF-4348182 and all analogues belonging to groups 1
and 2 completely rescued SP1-A3V replication irrespective of
their inhibitory activity against HIV-1. For example, both the ac-
tive analogue StA-MAT-17 and the completely inactive analogue
StA-MAT-27 rescued SP1-A3V replication to the same extent,
such that virus replication peaked 2 days earlier than for the WT
virus (Fig. 5). Rescue of the more severe SP1-A3T mutant was
achieved only by PF-46396 and a subset of analogues belonging to
groups 1 and 2 (StA-MAT-25, -18, and -30), but again, the capac-
ity to rescue was independent of the compound’s inhibitory activ-
ity against HIV-1 (Fig. 5 and Table 2). The lack of any replication
delay implies that the mutants are not under any selection pres-
sure. This was confirmed by sequencing of representative samples,
which demonstrated that upon rescue, the original SP1 residue 3
mutations were maintained without the acquisition of additional
mutations (Table 2). Intriguingly, in contrast to the complete lack
of SP1-A3T replication in the absence of the compound, delayed
FIG4 SP1 residue 3mutations confer resistance to PF-46396 analogues. The quantitativeCA-SP1 processing assay involvesHeLa cells being transfectedwithWT
pNL4-3 or derivatives containing the SP1-A3V or SP1-A3T mutation and cultured with 5 M compound or an equivalent volume of DMSO. Cells were
metabolically labeled for 2 h with [35S]Met-Cys, and released virions were pelleted by ultracentrifugation. Virus lysates were immunoprecipitated with HIV-Ig,
and processing of CA-SP1 to CA was analyzed by SDS-PAGE and fluorography, followed by phosphorimager analysis to quantify the percentage of CA-SP1
relative to total CA-SP1 plus CA in pelleted virus samples. Mean values from independent experiments are presented (n 3), and error bars indicate standard
deviations.
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replication was observed in the presence of group 1 and 2 ana-
logues that did not rescue this mutant, and the emergence of rep-
lication was accompanied by the loss of the SP1-A3T mutation
and acquisition of the SP1-A3V mutation. Conversion to SP1-
A3Vmust offer an advantage in the presence of these analogues, as
it requires 2 nucleotide changes compared to just 1 nucleotide
change to revert to theWT sequence. In contrast to the across-the-
board rescue of SP1-A3V observed for group 1 and 2 analogues,
no group 3 analogues rescued SP1-A3V or SP1-A3T (Fig. 5).
When virus replication occurred in the presence of a group 3
analogue, it was significantly delayed (9 days), and the SP1-A3V
mutation had reverted to the WT sequence.
The SP1 residue 3 mutations cause defective virus particle as-
sembly and release, which is again more severe in the SP1-A3T
mutant (39). PF-46396 partially corrects defective virus particle
production in these mutants (4); therefore, we sought to deter-
mine if a representative subset of analogues that rescued SP1-A3V
or SP1-A3T replication also restored virus particle production by
measuring virus release efficiency (Fig. 6 and 7). Overall, the abil-
ity of an analogue to rescue defective virus replication correlated
with a partial restoration of virus particle release efficiency and
was independent of the analogue’s inhibitory activity.
FIG 5 Effect of PF-46393 analogues on replication kinetics of HIV-1 SP1 residue 3 mutants in Jurkat T cells. Jurkat T cells were transfected with pNL4-3/WT,
pNL4-3/SP1-A3V (A), or pNL4-3/SP1-A3T (B) and cultured with 5 M compound or an equivalent volume of DMSO. Cells were split at regular intervals, and
supernatantswere reserved at each time point for RT analysis. The dashed line represents the peak day (day 12) ofWTNL4-3 replicationwhen cultured inDMSO.
TABLE 2 Effects of a subset of PF-46396 analogues on HIV-1 SP1
residue 3 mutant replication kinetics in Jurkat T cellsa
NL4-3
variant Analogue
Day of peak replication
compared to that with
DMSO Mutation acquisition
WT DMSO 0 ND
SP1-A3V DMSO 11 Reverted to WT
SP1-A3V PF-46396 3 ND
SP1-A3V PF-4348182 2 ND
SP1-A3V StA-MAT-21 0 ND
SP1-A3V StA-MAT-23 0 ND
SP1-A3V StA-MAT-25 0 ND
SP1-A3V StA-MAT-18 3 SP1-A3V maintained
SP1-A3V StA-MAT-27 0 ND
SP1-A3V StA-MAT-30 3 SP1-A3V maintained
SP1-A3T DMSO No replication ND
SP1-A3T PF-46396 0 ND
SP1-A3T PF-4348182 No replication ND
SP1-A3T StA-MAT-21 7 SP1-A3V
SP1-A3T StA-MAT-23 7 SP1-A3V
SP1-A3T StA-MAT-25 2 SP1-A3T maintained
SP1-A3T StA-MAT-18 0 SP1-A3T maintained
SP1-A3T StA-MAT-27 7 SP1-A3V
SP1-A3T StA-MAT-30 3 SP1-A3T maintained
a ND, not determined.
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SP1-A3V virus release efficiency was significantly increased in
the presence of all the compounds tested that have the ability to
rescue SP1-A3V replication, with the exception of PF-4348182.
Despite the fact that treatment with PF-434812 did not result in a
statistically significant increase in virus release efficiency, the data
suggest that this compound likely complies with the overall trend,
as the mean virus release efficiency in its presence increased to
44%, compared to 22% in the presence of DMSO (negative con-
trol). Reassuringly, the group 3 analogue StA-MAT-7, which did
not rescue SP1-A3V replication, also did not restore any virus
particle release efficiency. SP1-A3T virus release efficiency was
significantly increased in the presence of PF-46396, StA-MAT-18,
and StA-MAT-30, which rescued SP1-A3T replication. Treatment
with PF-4348182, which did not rescue SP1-ATV replication, did
not restore virus particle release efficiency, as no statistically sig-
nificant increase was observed.
Overall, an analogue’s ability to rescue virus replication corre-
lated with a partial restoration of virus particle production that
was generally equivalent to the level of restoration achieved by
PF-46396. The ability of an analogue to rescue the defective phe-
notype conferred by the SP1 residue 3mutations was independent
of inhibitory activity against HIV-1, and rescue implies that the
analogue was able to interact with the mutant Gag protein con-
cerned.
Rescue of CA mutants by inactive PF-46396 analogues. PF-
46396 resistance mutations located in CA also impose severe rep-
lication and virus production defects on HIV-1 that can be res-
cued in a compound-dependent manner by PF-46396 but not
BVM (4). These mutations include a mutation located at the CA
CTD tail (CA-G225D) and 3 mutations that map to the MHR
(CA-G156E, CA-P157S, and CA-P160L). Given our observation
that inactive analogues can rescue the SP1 residue 3mutations, we
investigated if a selection of our inactive analogues (PF-4348182
and StA-MAT-23, -27, and -7) could rescue these CA mutants
FIG 6 Effect of PF-46396 analogues on virus release efficiency of the SP1-A3V mutant. HeLa cells were transfected with pNL4-3/WT or pNL4-3/SP1-A3V and
cultured with 5Mcompound or an equivalent volume of DMSO. Cells weremetabolically labeled for 2 h with [35S]Met-Cys, and released virions were pelleted
by ultracentrifugation. (A) Cell and virus lysates were immunoprecipitated with HIV-Ig and analyzed by SDS-PAGE and fluorography. (B) Phosphorimager
analysis was done to quantify virus release efficiency, calculated as the amount of particle-associated Gag as a fraction of total (cell and virion) Gag. Statistical
significance was assessed by using one-way analysis of variance followed byDunnett’s multiple-comparison posttest to compare SP1-A3V virus release efficiency
in the presence of DMSO to that in the presence of each test compound. *, P 0.05; **, P 0.01; ***, P 0.001. Mean values from independent experiments
are presented (n  3 to 6), and error bars indicate standard deviations. Statistical analysis was performed by using GraphPad Prism version 6 software. The
compound’s ability to inhibit HIV-1 is indicated (A, active; I, intermediate activity; N, nonactive).
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(Fig. 8). StA-MAT-7 did not rescue the replication of any of the
CA mutants; however, this was not surprising given that none of
the group 3 analogues rescued the SP1 residue 3 mutants. Of the
other three analogues tested that rescued SP1-A3V, only StA-
MAT-23 and -27 were able to completely rescue the replication of
just one CAmutant, CA-P157S. The CA-G156Emutant exhibited
moderately delayed replication (7 days) in the presence of StA-
MAT-23; unfortunately, this sample was not collected for se-
quencing, and therefore, it is not possible to distinguish between
the possibility that StA-MAT-23 is capable of partially rescuing
CA-G156E replication and the possibility that the virus acquired a
mutation that either reverted the virus back to theWT sequence or
provided a second-site mutation that compensated for the repli-
cation defect imposed by CA-G156E. It was previously demon-
strated that these CA mutants can acquire such second-site com-
pensatory mutations (4); therefore, this is likely to have also
occurred in this experiment when the replication of both CA-
G156E and CA-P157S emerged after a significant delay.
An analogue’s ability to rescue CA-P157S replication also cor-
related with partial restoration of the particle production defect
imposed on HIV-1 by this mutation (Fig. 9). The compounds
(PF-46396 and StA-MAT-23 and -27) that rescuedCA-P175S rep-
lication exhibited a statistically significant increase in CA-P175S
virus release efficiency. In contrast, PF-4348182, which did not
rescue CA-P175S replication, also did not cause a statistically sig-
nificant increase in CA-P175S virus release efficiency. Although
not all the inactive analogues tested were capable of rescuing the
CA-P157S mutant, this capability was independent of antiviral
activity because PF-46396 can also rescue CA-P157S along with
the other CA mutants.
Inactive PF-46396 analogues are capable of associating with
WT and mutant Gag proteins in the context of immature virus
particles. We have demonstrated that some of the inactive PF-
46396 analogues are capable of rescuing defective HIV-1 replica-
tion and virus particle production in a compound-dependent
manner. The defective replication phenotype is imposed on
HIV-1 by a variety of mutations that confer PF-46396 resistance
and map to the CA-SP1 junction or MHR of Gag. The observed
compound dependence strongly suggests that the relevant inac-
tive analogues bind to mutant Gag molecules in order to facilitate
rescue. We sought to further demonstrate that inactive analogues
are capable of binding mutant Gag proteins by determining if
inactive analogues are incorporated into immature virus particles
using a variation of a previously reported mass spectrometry-
basedmethod that demonstrated BVM incorporation into imma-
ture HIV-1 particles (57). The experiment was conducted in the
context of assembled virus particles, rather than using purified
Gag protein, because it was previously shown that maturation
inhibitor binding requires virus assembly (33, 56, 57).
To conduct this experiment, we selected the SP1-A3V mutant
because (i) it was rescued in a compound-dependent manner by
the greatest variety of analogues and (ii) it imposes the least severe
defect in virus particle production compared to the othermutants
investigated (SP1-A3T and CA-P157S) and, hence, is most likely
to generate sufficient particles to enable us to determine analogue
incorporation. We tested the following inactive compounds: PF-
4348182 and StA-MAT-23, -30, and -7 from groups 1, 2, and 3,
respectively. The incorporation of PF-46396 into both WT and
SP1-A3V immature particles was also determined. Immature par-
ticles were produced in the presence of the compound. Relative
levels of analogue incorporation were normalized to the amount
of Gag in each purified virus particle sample, and levels of PF-
46396 incorporation intoWT particles were set at 100% (Fig. 10).
The inactive analogues PF-4348182 and StA-MAT-23 and -30,
which are capable of rescuing the replication defect imposed on
HIV-1 by the SP1-A3V mutation, were incorporated into SP1-
A3V immature particles to the same extent as the active com-
pound PF-46396 (Fig. 10B). As expected, the inactive analogue
FIG 7 Effects of PF-46396 analogues on virus release efficiency of the SP1-A3T mutant. HeLa cells were transfected with pNL4-3/WT or pNL4-3/SP1-A3T and
cultured with 5Mcompound or an equivalent volume of DMSO. Cells weremetabolically labeled for 2 h with [35S]Met-Cys, and released virions were pelleted
by ultracentrifugation. (A) Cell and virus lysates were immunoprecipitated with HIV-Ig and analyzed by SDS-PAGE and fluorography. (B) Phosphorimager
analysis was used to quantify virus release efficiency, calculated as the amount of particle-associated Gag as a fraction of total (cell plus virion) Gag. Statistical
significance was assessed by using one-way analysis of variance followed byDunnett’s multiple-comparison posttest to compare SP1-A3T virus release efficiency
in the presence of DMSO to that in the presence of each test compound. *, P 0.05; **, P 0.01; ***, P 0.001. Mean values from independent experiments
are presented (n  2 to 4), and error bars indicate standard deviations. Statistical analysis was performed by using GraphPad Prism version 6 software. The
compound’s ability to inhibit HIV-1 is indicated (A, active; I, intermediate activity; N, nonactive).
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StA-MAT-7, which is not capable of rescuing SP1-A3V virus rep-
lication, was not incorporated into SP1-A3V immature particles
(Fig. 10B). Interestingly, all the compounds that were incorpo-
rated into SP1-A3V immature particles were present at a level that
was approximately half of that observed for PF-46396 incorpora-
tion into WT immature virus particles (Fig. 10B). Overall, these
data support the hypothesis that inactive compounds are capable
of interacting with mutant Gag proteins in order to rescue defec-
tive HIV-1 in a compound-dependent manner.
The observed ability of inactive compounds to interact with
mutant Gag may be a consequence of a conformational change in
Gag, caused by themutations, which couldmodify either the com-
pound binding site and/or binding affinity. Therefore, it cannot
necessarily be assumed that inactive compounds can interact with
WT Gag. We used a mass spectrometry assay to determine if the
same inactive analogues are also incorporated intoWT immature
particles (Fig. 10C and D). As anticipated, the group 3 analogue
StA-MAT-7 was not incorporated into WT immature particles,
suggesting that this analogue has lost its ability to interact with
Gag. PF-4348182 was detected at very low levels in WT immature
virus particles, suggesting that this compound interacts only
weakly, if at all, with WT Gag. This demonstrates that a com-
pound’s ability to bind mutant Gag cannot be directly extrapo-
lated to infer an ability to bind WT Gag. The inactive analogues
StA-MAT-23 and -30, however, were incorporated into WT par-
ticles albeit at reduced levels compared to PF-46396. The incor-
poration of StA-MAT-23, however, is remarkably efficient given
that this analogue exhibits absolutely no inhibitory activity against
HIV-1.
We have clearly demonstrated that two inactive analogues
(StA-MAT-23 and -30) are capable of interacting with WT Gag
albeit with a reduced affinity compared to PF-46396. We next
sought to determine if inactive analogue binding could interfere
with PF-46396 binding and, hence, its activity. This is important
because reduced levels of inactive analogue incorporation into
WT particles may reflect binding to low-affinity sites on Gag
rather than at the primary maturation inhibitor-binding site. To
do this, we performed a competition assay with PF-46396 and
StA-MAT-23 using various combinations of concentrations (Fig.
11). As expected, increasing concentrations of PF-46396 resulted
in a dose-dependent increase in the amount of the uncleaved CA-
SP1 intermediate (Fig. 11B). Increasing concentrations of StA-
MAT-23 did not result in any significant accumulation of CA-SP1
(Fig. 11C). When the PF-46396 concentration remained constant
at 1 M, simultaneous treatment with increasing concentrations
of StA-MAT-23 resulted in decreased CA-SP1 levels compared to
treatment with 1 M PF-46396 alone. This decrease in CA-SP1
levels was statistically significant when the highest concentration
(5 M) of StA-MAT-23 was tested (Fig. 11D). We next examined
PF-46396 activity at various concentrations, either alone or in
combination with 1 M StA-MAT-23 (Fig. 11E). At all concen-
trations tested, the inhibitory activity of PF-46396 was signifi-
FIG8 Effect of PF-46393 analogues on pNL4-3CAmutant replication in Jurkat T cells. Jurkat T cells were transfectedwith pNL4-3/WTor SP1-A3V,CA-G156E,
CA-157S, CA-P160L, or CA-G225Dderivatives and culturedwith either 5Mcompound or an equivalent volume ofDMSO. Cells were split at regular intervals,
and supernatants were reserved at each time point for RT analysis. The dashed line represents the peak day (day 10) of WT NL4-3 replication when cultured in
DMSO.
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cantly reduced when it was combined with 1 M StA-MAT-23.
Collectively, these data demonstrate that the inactive analogue
StA-MAT-23 is able to interfere with the binding and, thus, the
activity of PF-46396, suggesting that these two compounds com-
pete for Gag binding, possibly at the same or an overlapping bind-
ing site(s).
DISCUSSION
How chemically distinct pyridone-based (PF-46396) and bet-
ulinic acid-derived (BVM) HIV-1 maturation inhibitors appar-
ently act by similar modes of action has yet to be determined.
While structure-activity relationships of betulinic acid-derived
compounds have been described previously (38, 46–48, 68, 69),
the chemical determinants of PF-46396 antiviral activity have not
been reported (35). In this study, we utilized a novel analogue
series to examine PF-46396 structure-activity relationships with
respect to compound antiviral activity and the ability to bind Gag.
We demonstrate that the tert-butyl group in the PF-46396 phe-
nyl ring is essential for antiviral activity and cannot be replaced
with a hydrogen, methyl, methoxy, trifluoromethyl, or chloro
group. The presence of the tert-butyl group, however, is not an
absolute requirement for Gag binding, because the inactive ana-
logue StA-MAT-23, in which a methyl group replaces the tert-
butyl group, is still incorporated relatively efficiently intoWT im-
mature particles. Indeed, StA-MAT-23 can antagonize PF-46396
activity, suggesting that these two compounds compete for Gag
binding, possibly at the same or overlapping binding sites. None-
theless, the contacts made by the tert-butyl group almost certainly
improve the Gag binding efficiency (at least compared to the
methyl group), because levels of incorporated StA-MAT-23 are
	30% lower than those of PF-46396 in WT immature virus par-
ticles. Instead, our data suggest that the bulky tert-butyl group
likely occupies space in the putative hydrophobic inhibitor-bind-
ing pocket such that its presence directly blocks PR access to the
CA-SP1 cleavage site. Alternatively, the tert-butyl group may in-
fluence an allosteric site causing an alteration in the conforma-
tion, exposure, or flexibility of this region of Gag, such that PR
cleavage of the CA-SP1 site is less efficient. Both of these possibil-
ities were previously hypothesized to be modes of action utilized
by maturation inhibitors (4, 27, 32, 58), and evidence that BVM
bindsGag sequences directly overlapping theCA-SP1 cleavage site
was generated by using photoaffinity analogues of BVM (58).
Overall, StA-MAT-23 clearly demonstrates that a completely in-
active analogue of PF-46363 is capable of some binding to WT
immature virus particles, which is likely to be at or overlapping the
primary maturation inhibitor-binding pocket in Gag. The impli-
cation of this observation is that at least some Gag binding may
not be enough for inhibitor antiviral activity. Similarly, it has been
proposed that binding of BVM to immature particles may not be
sufficient for its antiviral activity, because particles assembled
from Gag containing certain resistance mutations (CA-L231M or
SP1-A1M) retain an intermediate capacity to incorporate and,
hence, bind BVM (61).
The 2-aminoindan group of PF-46396 is important for an-
tiviral activity, as the loss of this group (group 3 analogues)
results in completely inactive compounds despite the presence
of the tert-butyl group (StA-MAT-5). However, the presence of
the 2-aminoindan group does not guarantee Gag binding be-
cause PF-4348182, which contains this group, was only very
weakly incorporated into WT immature particles. PF-4348182
has both the tert-butyl and trifluoromethyl groups replaced,
making assessments of the impact of the individual substitutions
difficult. However, as discussed above, the tert-butyl groupmakes
some contribution to WT Gag binding efficiency; therefore, it
seems likely that replacement of the tert-butyl group by the 2-pyr-
idyl group contributes to the loss of PF-4348182 binding. Despite
the fact that the 2-aminoindan groupmakes a major contribution
to the antiviral activity of PF-46396, its presence is not essential for
FIG 9 Effect of inactive PF-46396 analogues on virus release efficiency of the CA-P175S mutant. HeLa cells were transfected with pNL4-3/WT or pNL4-3/CA-
P175S and cultured with 5 M compound or an equivalent volume of DMSO. Cells were metabolically labeled for 2 h with [35S]Met-Cys, and released virions
were pelleted by ultracentrifugation. (A) Cell and virus lysates were immunoprecipitated with HIV-Ig and analyzed by SDS-PAGE and fluorography. (B)
Phosphorimager analysis was performed to quantify virus release efficiency, calculated as the amount of particle-associated Gag as a fraction of total (cell and
virion)Gag. Statistical significancewas assessed by using one-way analysis of variance followedbyDunnett’smultiple-comparisonposttest to compareCA-P157S
virus release efficiency in the presence of DMSO to that in the presence of each test compound. *, P  0.05; **, P  0.01; ***, P  0.001. Mean values from
independent experiments are presented (n 3), and error bars indicate standard deviations. Statistical analysis was performed by using GraphPad Prism version
6 software. The compound’s ability to inhibit HIV-1 is indicated (A, active; I, intermediate activity; N, nonactive).
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Gag binding, as its replacement by an aminomethyl-cyclohexane
(StA-MAT-30) results in an inactive analogue, which is incorpo-
rated into WT immature particles although less efficiently than
PF-46396. Similarly, replacement by benzylamine (StA-MAT-18)
leads to intermediate antiviral activity, and hence, a degree of Gag
bindingmust occur for this analogue.However, the incorporation
of a C4 substituent in the aryl ring of the benzylamine unit (StA-
MAT-27, -28, and -29) abolishes any antiviral activity.
Assessment of the antiviral activities of analogues inwhich only
the trifluoromethyl group has been changed (StA-MAT-17 and
-21) showed that while this group appears optimal for antiviral
activity, it is not essential because its replacement can be tolerated
(by hydrogen or chlorine at least). The nonessential role of the
trifluoromethyl group is related to antiviral activity in the context
of WT Gag; however, this group appears to play a role in the
compound-dependent rescue of the defective SP1-A3T HIV-1
FIG 10 Incorporation of PF-46396 analogues into immature WT or SP1-A3V HIV-1 particles. HeLa cells were transfected with pNL4-3/PR/WT or pNL4-3/
PR/SP1-A3V and treated with 5 M compound. Virus particles were concentrated by ultracentrifugation through a 20% sucrose cushion and purified by
equilibrium ultracentrifugation on a linear 30 to 70% sucrose gradient. (A and C) Peak fractions were pooled, and total Gag quantitated by immunodetection.
Compounds in pooled peak fractions were extracted, and the amount of the compound present was quantitated by mass spectrometric analysis. (B and D) The
relative incorporation of the compoundwas normalized to the amount of Gag in each sample and is represented as a percentage of the PF-46396 control. Batches
1 and 2 represent two independent experiments.
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mutant (see below). The optimal but nonessential role of the tri-
fluoromethyl group in the context of WT Gag binding suggests
that this site provides an opportunity to attach tags, such as an
azido group, as utilized by Nguyen et al. (58), to facilitate detailed
mapping of the PF-46396-binding site. This will allow further un-
derstanding of the relationship between antiviral activity and Gag
binding and of how structurally distinct HIV-1maturation inhib-
itors act by the same mode of action.
Overall, we have utilized this analogue series to dissect the con-
tribution that different moieties of PF-46396make toward antivi-
ral activity andWTGag binding and have started to determine the
relationship between these two essential properties. Our analyses
allow us to divide the analogues tested into three categories: (i)
analogues that retained antiviral activity and, hence, WT Gag
binding (StA-MAT-17 and -21); (ii) analogues that lost antiviral
activity but retained some capacity to bindWTGag (StA-MAT-23
and -30); and (iii) analogues that lost antiviral activity and the
ability to bind WT Gag (PF-4348182 and StA-MAT-7). It seems
likely that the inactive analogues that retain some capacity to bind
WT Gag interact with the putative maturation inhibitor-binding
site, as the analogue StA-MAT-23 interferes with PF-46396 activ-
ity, despite reduced levels of StA-MAT-23 incorporation intoWT
immature particles compared to PF-46396.
We also demonstrated that inactive analogues can be incorpo-
rated intomutant immature particles that are assembled fromGag
molecules that contain the SP1-A3Vmutation.When an analogue
was incorporated into these mutant particles, it was independent
of antiviral activity, as inactive compounds were incorporated as
efficiently as PF-46396. Analogue incorporation into SP1-A3V
immature particles correlatedwith their ability to rescue SP1-A3V
replication in a compound-dependent manner. Compound de-
pendency strongly suggests that rescue is facilitated by an ana-
logue’s capacity to interact with mutant Gag. Given that all ana-
logues, with the exception of compounds in group 3, were capable
of rescuing SP1-A3V, it is therefore reasonable to assume that
these analogues are also capable of some interaction with SP1-
A3V mutant Gag.
Interestingly, analogue incorporation into SP1-A3V immature
particleswas about half as efficient as PF-46396 incorporation into
WT immature particles. At present, we cannot exclude the possi-
bility that incorporation of compounds into SP1-A3V immature
particles occurs at low-affinity sites inGag that are unrelated to the
maturation inhibitor-binding site. However, we think that this is
unlikely, as the SP1-A3Vmutation maps to the region of Gag that
has been implicated inmaturation inhibitor activity, and this mu-
tation confers resistance to both PF-46396 and BVM (4, 39). Our
FIG 11 The inactive analogue StA-MAT-23 interferes with PF-46396 activity. HeLa cells were transfected with pNL4-3/WT and cultured with the indicated
concentrations of PF-46396 and/or StA-MAT-23. Cells were metabolically labeled for 2 h with [35S]Met-Cys, and released virions were pelleted by ultracentrif-
ugation. (A) Virus lysates were immunoprecipitated with HIV-Ig, and processing of CA-SP1 to CA was analyzed by SDS-PAGE and fluorography. (B and C)
Phosphorimager analysis was performed to quantify the percentage of CA-SP1 relative to total CA-SP1 plus CA in pelleted virus samples. The data are plotted as
the percentage of CA-SP1 in the presence of increasing concentrations of PF-46396 (B) or StA-MAT-23 (C). (D) The percentage of CA-SP1 in the presence of 1
M PF-46396 was compared to the percentage of CA-SP1 in the presence of 1 M PF-46396 plus increasing concentrations of StA-MAT-23. Statistical
significance was assessed by using one-way analysis of variance with Dunnett’s multiple-comparison posttest. *, P 0.05. (E) The percentage of CA-SP1 in the
presence of increasing concentrations of PF-46396 was compared with that in the presence of the equivalent concentration of PF-46396 plus 1MStA-MAT-23.
Statistical significance was assessed by using one-way analysis of variance with Bonferroni’s multiple-comparison posttest. *, P 0.05; **, P 0.01.Mean values
from independent experiments are presented (n 3), and error bars indicate standard deviations. Statistical analysis was preformed by using GraphPad Prism
version 6 software.
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data support the hypothesis that the mechanism of SP1-A3V re-
sistance is not via the prevention of inhibitor binding, but instead,
the mutation causes a conformational change in Gag that permits
PR access to the CA-SP1 cleavage site even when the compound is
bound (39). In addition, compound dependency reverses defec-
tive replication and particle production imposed on HIV-1 by the
SP1-A3Vmutation, implying that compound interaction directly
influences the function of the CA-SP1 region of Gag to which the
maturation inhibitor-binding pocket has beenmapped.However,
our data clearly suggest that the conformation of WT Gag is dif-
ferent from that of SP1-A3V Gag due to the differential incorpo-
ration of PF-46396, PF-4348182, StA-MAT-23, and StA-MAT-30
into immature particles assembled from each of these Gag mole-
cules. While all of these compounds were incorporated as effi-
ciently as each other into SP1-A3V particles (at least at 5 M),
variable incorporation intoWT immature particles was observed,
as analogues exhibited reduced (StA-MAT-23 and -30) or no (PF-
4348182) incorporation compared to PF-46396.
Analogue incorporation into SP1-A3V particles appears to be
highly flexible, as analogues with modifications of the 2-aminoin-
dan, tert-butyl, and/or trifluoromethyl groups within PF-46396
were all tolerated. Indeed, as discussed above, it can be assumed
that all analogues that rescue SP1-A3V in a compound-dependent
manner are capable of some interaction with SP1-A3V Gag. The
apparent plasticity of the compound-binding site created by the
SP1-A3Vmutation is not conferred by another maturation inhib-
itor resistance mutation, SP1-A3T, which maps to the same SP1
residue but imposes a more severe replication and particle pro-
duction phenotype on HIV-1 (39). Rescue of SP1-A3T was con-
fined to PF-46396 and just three analogues (StA-MAT-25, -18,
and -30), and the presence of the trifluoromethyl group appeared
to be necessary but not sufficient to rescue this mutant. Differen-
tial rescue of theCAMHRmutantswas also observed in this study.
However, the parental compound PF-46396 was capable of rescu-
ing all the MHR and SP1 mutants studied. Overall, this suggests
that an analogue’s capacity to rescue defective HIV-1 can be influ-
enced by the effect of the mutation in Gag and/or the chemical
structure of the analogue. Unfortunately, the lack of atomic-res-
olution structural information for the CA-SP1 region of Gag (17,
27) makes it challenging to interpret why a particular combina-
tion of a mutation and an analogue facilitates rescue.
In conclusion, we have utilized a series of analogues to deter-
mine PF-46396 structure-activity relationships with respect to an-
tiviral activity and binding to both WT and mutant Gag proteins.
The lack of a correlation between an analogue’s ability to bindGag
and its antiviral activity enabled us to start to dissect the contribu-
tion that different components of the PF-46396 structure make to
each of these essential roles and/or the relationship between them.
ACKNOWLEDGMENTS
We thank Christopher Simmonds-Riach for management of the category
3 biosafety containment facility at the University of St Andrews and John
Nicholson and Ashley Pearson for management of radioactive sources at
the University of St Andrews.We thank ChristopherMoffat for advice on
statistical analysis. We thank the EPSRC National Spectrometry Service
Centre, Swansea, United Kingdom. HIV-Ig was obtained through the
AIDS Research and Reference Reagent Program, Division of AIDS,
NIAID, NIH.
C.M., L.P., F.T., T.K.S., and C.S.A. executed and analyzed the experi-
ments; T.K.S., N.J.W., and C.S.A. conceived of, designed, and interpreted
data from the experiments; and T.K.S., N.J.W., andC.S.A. wrote theman-
uscript.
This work was funded by the University of St Andrews, a Society for
AppliedMicrobiology new lecturer research grant awarded to C.S.A., and
a Wellcome Trust grant (093228) awarded to T.K.S. The funders had no
role in the study design, data collection and interpretation, or the decision
to submit the work for publication.
FUNDING INFORMATION
This work, including the efforts of Terry K. Smith, was funded by Well-
come Trust (093228). This work, including the efforts of Catherine S.
Adamson, was funded by Society for AppliedMicrobiology (SfAM) (New
Lecturer Research Grant).
REFERENCES
1. Gamble TR, Yoo S, Vajdos FF, von Schwedler UK, Worthylake DK,
Wang H, McCutcheon JP, Sundquist WI, Hill CP. 1997. Structure of the
carboxyl-terminal dimerization domain of the HIV-1 capsid protein. Sci-
ence 278:849–853. http://dx.doi.org/10.1126/science.278.5339.849.
2. von Schwedler UK, Stray KM, Garrus JE, Sundquist WI. 2003. Func-
tional surfaces of the human immunodeficiency virus type 1 capsid pro-
tein. J Virol 77:5439–5450. http://dx.doi.org/10.1128/JVI.77.9.5439-5450
.2003.
3. Mammano F, Ohagen A, Hoglund S, Gottlinger HG. 1994. Role of the
major homology region of human immunodeficiency virus type 1 in vi-
rion morphogenesis. J Virol 68:4927–4936.
4. Waki K, Durell SR, Soheilian F, Nagashima K, Butler SL, Freed EO.
2012. Structural and functional insights into theHIV-1maturation inhib-
itor binding pocket. PLoS Pathog 8:e1002997. http://dx.doi.org/10.1371
/journal.ppat.1002997.
5. Guo X, Roldan A, Hu J, Wainberg MA, Liang C. 2005. Mutation of the
SP1 sequence impairs both multimerization and membrane-binding ac-
tivities of human immunodeficiency virus type 1 Gag. J Virol 79:1803–
1812. http://dx.doi.org/10.1128/JVI.79.3.1803-1812.2005.
6. Liang C, Hu J, Russell RS, Roldan A, Kleiman L, Wainberg MA. 2002.
Characterization of a putative alpha-helix across the capsid-SP1 boundary
that is critical for the multimerization of human immunodeficiency virus
type 1 gag. J Virol 76:11729–11737. http://dx.doi.org/10.1128/JVI.76.22
.11729-11737.2002.
7. Liang C, Hu J, Whitney JB, Kleiman L, Wainberg MA. 2003. A struc-
turally disordered region at theC terminus of capsid plays essential roles in
multimerization and membrane binding of the gag protein of human
immunodeficiency virus type 1. J Virol 77:1772–1783. http://dx.doi.org
/10.1128/JVI.77.3.1772-1783.2003.
8. Morikawa Y, Hockley DJ, Nermut MV, Jones IM. 2000. Roles of matrix,
p2, and N-terminal myristoylation in human immunodeficiency virus
type 1 Gag assembly. J Virol 74:16–23. http://dx.doi.org/10.1128/JVI.74.1
.16-23.2000.
9. Ono A, Demirov D, Freed EO. 2000. Relationship between human
immunodeficiency virus type 1 Gag multimerization and membrane
binding. J Virol 74:5142–5150. http://dx.doi.org/10.1128/JVI.74.11.5142
-5150.2000.
10. Erickson-Viitanen S, Manfredi J, Viitanen P, Tribe DE, Tritch R,
Hutchison CA, III, Loeb DD, Swanstrom R. 1989. Cleavage of HIV-1 gag
polyprotein synthesized in vitro: sequential cleavage by the viral protease.
AIDS Res Hum Retroviruses 5:577–591. http://dx.doi.org/10.1089/aid
.1989.5.577.
11. Krausslich HG, Schneider H, Zybarth G, Carter CA, Wimmer E. 1988.
Processing of in vitro-synthesized gag precursor proteins of human im-
munodeficiency virus (HIV) type 1 by HIV proteinase generated in Esch-
erichia coli. J Virol 62:4393–4397.
12. Mervis RJ, Ahmad N, Lillehoj EP, Raum MG, Salazar FH, Chan HW,
Venkatesan S. 1988. The gag gene products of human immunodeficiency
virus type 1: alignment within the gag open reading frame, identification
of posttranslational modifications, and evidence for alternative gag pre-
cursors. J Virol 62:3993–4002.
13. Pettit SC, Moody MD, Wehbie RS, Kaplan AH, Nantermet PV, Klein
CA, Swanstrom R. 1994. The p2 domain of human immunodeficiency
virus type 1Gag regulates sequential proteolytic processing and is required
to produce fully infectious virions. J Virol 68:8017–8027.
14. Tritch RJ, Cheng YE, Yin FH, Erickson-Viitanen S. 1991. Mutagenesis of
PF-46396 Structure-Activity Relationships
September 2016 Volume 90 Number 18 jvi.asm.org 8195Journal of Virology
 o
n
 August 29, 2016 by ST ANDREW
S UNIV
http://jvi.asm.org/
D
ow
nloaded from
 
protease cleavage sites in the human immunodeficiency virus type 1 gag
polyprotein. J Virol 65:922–930.
15. Wiegers K, Rutter G, Kottler H, Tessmer U, Hohenberg H, Krausslich
HG. 1998. Sequential steps in human immunodeficiency virus particle
maturation revealed by alterations of individual Gag polyprotein cleavage
sites. J Virol 72:2846–2854.
16. Adamson CS, Freed EO. 2007. Human immunodeficiency virus type 1
assembly, release, and maturation. Adv Pharmacol 55:347–387. http://dx
.doi.org/10.1016/S1054-3589(07)55010-6.
17. Freed EO. 2015. HIV-1 assembly, release and maturation. Nat Rev Mi-
crobiol 13:484–496. http://dx.doi.org/10.1038/nrmicro3490.
18. Sundquist WI, Krausslich H-G. 2012. HIV-1 assembly, budding, and
maturation. Cold Spring Harb Perspect Med 2:a006924. http://dx.doi.org
/10.1101/cshperspect.a006924.
19. Ganser-Pornillos BK, Yeager M, Pornillos O. 2012. Assembly and archi-
tecture ofHIV.AdvExpMedBiol 726:441–465. http://dx.doi.org/10.1007
/978-1-4614-0980-9_20.
20. Konvalinka J, Krausslich HG, Muller B. 2015. Retroviral proteases and
their roles in virion maturation. Virology 479–480:403–417. http://dx
.doi.org/10.1016/j.virol.2015.03.021.
21. Accola MA, Hoglund S, Gottlinger HG. 1998. A putative alpha-helical
structure which overlaps the capsid-p2 boundary in the human immuno-
deficiency virus type 1 Gag precursor is crucial for viral particle assembly.
J Virol 72:2072–2078.
22. Kaplan AH, Zack JA, Knigge M, Paul DA, Kempf DJ, Norbeck DW,
Swanstrom R. 1993. Partial inhibition of the human immunodeficiency
virus type 1 protease results in aberrant virus assembly and the formation
of noninfectious particles. J Virol 67:4050–4055.
23. Krausslich HG, Facke M, Heuser AM, Konvalinka J, Zentgraf H. 1995.
The spacer peptide between human immunodeficiency virus capsid and
nucleocapsid proteins is essential for ordered assembly and viral infectiv-
ity. J Virol 69:3407–3419.
24. Pettit SC, Henderson GJ, Schiffer CA, Swanstrom R. 2002. Replacement
of the P1 amino acid of human immunodeficiency virus type 1 Gag pro-
cessing sites can inhibit or enhance the rate of cleavage by the viral pro-
tease. J Virol 76:10226–10233. http://dx.doi.org/10.1128/JVI.76.20.10226
-10233.2002.
25. Lee SK, Harris J, Swanstrom R. 2009. A strongly transdominant muta-
tion in the human immunodeficiency virus type 1 gag gene defines an
Achilles heel in the virus life cycle. J Virol 83:8536–8543. http://dx.doi.org
/10.1128/JVI.00317-09.
26. Checkley MA, Luttge BG, Soheilian F, Nagashima K, Freed EO. 2010.
The capsid-spacer peptide 1 Gag processing intermediate is a dominant-
negative inhibitor of HIV-1 maturation. Virology 400:137–144. http://dx
.doi.org/10.1016/j.virol.2010.01.028.
27. Adamson CS. 2012. Protease-mediated maturation of HIV: inhibitors of
protease and the maturation process. Mol Biol Int 2012:604261. http://dx
.doi.org/10.1155/2012/604261.
28. Gulick RM, Mellors JW, Havlir D, Eron JJ, Gonzalez C, McMahon D,
Richman DD, Valentine FT, Jonas L, Meibohm A, Emini EA, Chod-
akewitz JA. 1997. Treatment with indinavir, zidovudine, and lamivudine
in adults with human immunodeficiency virus infection and prior anti-
retroviral therapy. N Engl J Med 337:734–739. http://dx.doi.org/10.1056
/NEJM199709113371102.
29. Hammer SM, Squires KE, Hughes MD, Grimes JM, Demeter LM,
Currier JS, Eron JJ, Jr, Feinberg JE, Balfour HH, Jr, Deyton LR,
Chodakewitz JA, Fischl MA. 1997. A controlled trial of two nucleoside
analogues plus indinavir in persons with human immunodeficiency virus
infection and CD4 cell counts of 200 per cubic millimeter or less. AIDS
Clinical Trials Group 320 Study Team. N Engl J Med 337:725–733.
30. Richman DD. 2001. HIV chemotherapy. Nature 410:995–1001. http://dx
.doi.org/10.1038/35073673.
31. Walensky RP, Paltiel AD, Losina E, Mercincavage LM, Schackman BR,
Sax PE, Weinstein MC, Freedberg KA. 2006. The survival benefits of
AIDS treatment in the United States. J Infect Dis 194:11–19. http://dx.doi
.org/10.1086/505147.
32. Adamson CS, Freed EO. 2010. Novel approaches to inhibiting HIV-1 repli-
cation. Antiviral Res 85:119–141. http://dx.doi.org/10.1016/j.antiviral.2009
.09.009.
33. Li F, Goila-Gaur R, Salzwedel K, Kilgore NR, Reddick M, Matallana C,
Castillo A, Zoumplis D, Martin DE, Orenstein JM, Allaway GP, Freed
EO, Wild CT. 2003. PA-457: a potent HIV inhibitor that disrupts core
condensation by targeting a late step inGag processing. ProcNatl Acad Sci
U S A 100:13555–13560. http://dx.doi.org/10.1073/pnas.2234683100.
34. Zhou J, Yuan X, Dismuke D, Forshey BM, Lundquist C, Lee KH, Aiken
C, Chen CH. 2004. Small-molecule inhibition of human immunodefi-
ciency virus type 1 replication by specific targeting of the final step of
virionmaturation. J Virol 78:922–929. http://dx.doi.org/10.1128/JVI.78.2
.922-929.2004.
35. Blair WS, Cao J, Fok-Seang J, Griffin P, Isaacson J, Jackson RL, Murray
E, Patick AK, Peng Q, Perros M, Pickford C, Wu H, Butler SL. 2009.
New small-molecule inhibitor class targeting human immunodeficiency
virus type 1 virion maturation. Antimicrob Agents Chemother 53:5080–
5087. http://dx.doi.org/10.1128/AAC.00759-09.
36. Keller PW, Adamson CS, Heymann JB, Freed EO, Steven AC. 2011.
HIV-1maturation inhibitor bevirimat stabilizes the immature Gag lattice.
J Virol 85:1420–1428. http://dx.doi.org/10.1128/JVI.01926-10.
37. Keller PW, Huang RK, England MR, Waki K, Cheng N, Heymann JB,
Craven RC, Freed EO, Steven AC. 2013. A two-pronged structural anal-
ysis of retroviral maturation indicates that core formation proceeds by a
disassembly-reassembly pathway rather than a displacive transition. J Vi-
rol 87:13655–13664. http://dx.doi.org/10.1128/JVI.01408-13.
38. Kanamoto T, Kashiwada Y, Kanbara K, Gotoh K, Yoshimori M, Goto
T, Sano K, Nakashima H. 2001. Anti-human immunodeficiency virus
activity of YK-FH312 (a betulinic acid derivative), a novel compound
blocking viral maturation. Antimicrob Agents Chemother 45:1225–1230.
http://dx.doi.org/10.1128/AAC.45.4.1225-1230.2001.
39. Adamson CS, Ablan SD, Boeras I, Goila-Gaur R, Soheilian F, Na-
gashima K, Li F, Salzwedel K, Sakalian M, Wild CT, Freed EO. 2006. In
vitro resistance to the human immunodeficiency virus type 1 maturation
inhibitor PA-457 (bevirimat). J Virol 80:10957–10971. http://dx.doi.org
/10.1128/JVI.01369-06.
40. Smith PF, Ogundele A, Forrest A, Wilton J, Salzwedel K, Doto J,
Allaway GP, Martin DE. 2007. Phase I and II study of the safety, virologic
effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-
(3=,3=-dimethylsuccinyl)betulinic acid (bevirimat) against human immu-
nodeficiency virus infection. Antimicrob Agents Chemother 51:3574–
3581. http://dx.doi.org/10.1128/AAC.00152-07.
41. McCallister S, Lalezari J, Richmond G, Thompson M, Harrigan R,
Martin D, Salzwedel K, Allaway G. 2008. HIV-1 Gag polymorphisms
determine treatment response to bevirimat (PA-457). Antivir Ther
13:A10.
42. Van Baelen K, Salzwedel K, Rondelez E, Van Eygen V, De Vos S,
Verheyen A, Steegen K, Verlinden Y, Allaway GP, Stuyver LJ. 2009.
Susceptibility of human immunodeficiency virus type 1 to thematuration
inhibitor bevirimat is modulated by baseline polymorphisms in Gag
spacer peptide 1. Antimicrob Agents Chemother 53:2185–2188. http://dx
.doi.org/10.1128/AAC.01650-08.
43. Adamson CS, Sakalian M, Salzwedel K, Freed EO. 2010. Polymorphisms
in Gag spacer peptide 1 confer varying levels of resistance to the HIV-1
maturation inhibitor bevirimat. Retrovirology 7:36. http://dx.doi.org/10
.1186/1742-4690-7-36.
44. Margot NA, Gibbs CS, Miller MD. 2010. Phenotypic susceptibility to
bevirimat in isolates fromHIV-1-infected patients without prior exposure
to bevirimat. Antimicrob Agents Chemother 54:2345–2353. http://dx.doi
.org/10.1128/AAC.01784-09.
45. Lu W, Salzwedel K, Wang D, Chakravarty S, Freed EO, Wild CT, Li F.
2011. A single polymorphism in HIV-1 subtype C SP1 is sufficient to
confer natural resistance to the maturation inhibitor bevirimat. Antimi-
crob Agents Chemother 55:3324–3329. http://dx.doi.org/10.1128/AAC
.01435-10.
46. Dang Z, Qian K, Ho P, Zhu L, Lee KH, Huang L, Chen CH. 2012.
Synthesis of betulinic acid derivatives as entry inhibitors against HIV-1
and bevirimat-resistant HIV-1 variants. Bioorg Med Chem Lett 22:5190–
5194. http://dx.doi.org/10.1016/j.bmcl.2012.06.080.
47. Dang Z, Ho P, Zhu L, Qian K, Lee KH, Huang L, Chen CH. 2013. New
betulinic acid derivatives for bevirimat-resistant human immunodefi-
ciency virus type-1. JMedChem 56:2029–2037. http://dx.doi.org/10.1021
/jm3016969.
48. Urano E, Ablan SD, Mandt R, Pauly GT, Sigano DM, Schneider JP,
Martin DE, Nitz TJ, Wild CT, Freed EO. 2016. Alkyl amine bevirimat
derivatives are potent and broadly active HIV-1 maturation inhibitors.
Antimicrob Agents Chemother 60:190–197. http://dx.doi.org/10.1128
/AAC.02121-15.
49. Worthylake DK, Wang H, Yoo S, Sundquist WI, Hill CP. 1999. Struc-
Murgatroyd et al.
8196 jvi.asm.org September 2016 Volume 90 Number 18Journal of Virology
 o
n
 August 29, 2016 by ST ANDREW
S UNIV
http://jvi.asm.org/
D
ow
nloaded from
 
tures of theHIV-1 capsid protein dimerization domain at 2.6A resolution.
Acta Crystallogr D Biol Crystallogr 55:85–92. http://dx.doi.org/10.1107
/S0907444998007689.
50. Schur FK, Hagen WJ, Rumlova M, Ruml T, Muller B, Krausslich HG,
Briggs JA. 2015. Structure of the immature HIV-1 capsid in intact virus
particles at 8.8 A resolution. Nature 517:505–508. http://dx.doi.org/10
.1038/nature13838.
51. Datta SAK, Temeselew LG, Crist RM, Soheilian F, Kamata A, Mirro J,
Harvin D, Nagashima K, Cachau RE, Rein A. 2011. On the role of the
SP1 domain in HIV-1 particle assembly: a molecular switch? J Virol 85:
4111–4121. http://dx.doi.org/10.1128/JVI.00006-11.
52. Morellet N, Druillennec S, Lenoir C, Bouaziz S, Roques BP. 2005.
Helical structure determined by NMR of the HIV-1(345-392)Gag
sequence, surrounding p2: implications for particle assembly and
RNA packaging. Protein Sci 14:375–386. http://dx.doi.org/10.1110/ps
.041087605.
53. Newman JL, Butcher EW, Patel DT, Mikhaylenko Y, Summers MF.
2004. Flexibility in the P2 domain of the HIV-1 Gag polyprotein. Protein
Sci 13:2101–2107. http://dx.doi.org/10.1110/ps.04614804.
54. Wright ER, Schooler JB, Ding HJ, Kieffer C, Fillmore C, Sundquist WI,
Jensen GJ. 2007. Electron cryotomography of immature HIV-1 virions
reveals the structure of the CA and SP1Gag shells. EMBO J 26:2218–2226.
http://dx.doi.org/10.1038/sj.emboj.7601664.
55. Bharat TA, Castillo Menendez LR, Hagen WJ, Lux V, Igonet S, Schorb
M, Schur FK, Krausslich HG, Briggs JA. 2014. Cryo-electron microscopy
of tubular arrays of HIV-1 Gag resolves structures essential for immature
virus assembly. Proc Natl Acad Sci U S A 111:8233–8238. http://dx.doi
.org/10.1073/pnas.1401455111.
56. Sakalian M, McMurtrey CP, Deeg FJ, Maloy CW, Li F, Wild CT,
Salzwedel K. 2006. 3-O-(3=,3=-Dimethysuccinyl)betulinic acid inhibits
maturation of the human immunodeficiency virus type 1 Gag precursor
assembled in vitro. J Virol 80:5716–5722. http://dx.doi.org/10.1128/JVI
.02743-05.
57. Zhou J, Huang L, Hachey DL, Chen CH, Aiken C. 2005. Inhibition of
HIV-1 maturation via drug association with the viral Gag protein in im-
mature HIV-1 particles. J Biol Chem 280:42149–42155. http://dx.doi.org
/10.1074/jbc.M508951200.
58. Nguyen AT, Feasley CL, Jackson KW, Nitz TJ, Salzwedel K, Air GM,
Sakalian M. 2011. The prototype HIV-1 maturation inhibitor, bevirimat,
binds to the CA-SP1 cleavage site in immature Gag particles. Retrovirol-
ogy 8:101. http://dx.doi.org/10.1186/1742-4690-8-101.
59. Adamson CS, Waki K, Ablan SD, Salzwedel K, Freed EO. 2009. Impact
of human immunodeficiency virus type 1 resistance to protease inhibitors
on evolution of resistance to thematuration inhibitor bevirimat (PA-457).
J Virol 83:4884–4894. http://dx.doi.org/10.1128/JVI.02659-08.
60. Fun A, van Maarseveen NM, Pokorna J, Maas RE, Schipper PJ, Kon-
valinka J, Nijhuis M. 2011. HIV-1 protease inhibitor mutations affect the
development of HIV-1 resistance to the maturation inhibitor bevirimat.
Retrovirology 8:70. http://dx.doi.org/10.1186/1742-4690-8-70.
61. Zhou J, Chen CH, Aiken C. 2006. Human immunodeficiency virus type
1 resistance to the small molecule maturation inhibitor 3-O-(3=,3=-
dimethylsuccinyl)-betulinic acid is conferred by a variety of single amino
acid substitutions at the CA-SP1 cleavage site in Gag. J Virol 80:12095–
12101. http://dx.doi.org/10.1128/JVI.01626-06.
62. Fontana J, Keller PW, Urano E, Ablan SD, Steven AC, Freed EO. 2016.
Identification of an HIV-1 mutation in spacer peptide 1 that stabilizes the
immature CA-SP1 lattice. J Virol 90:972–978. http://dx.doi.org/10.1128
/JVI.02204-15.
63. Adachi A, Gendelman HE, Koenig S, Folks T, Willey R, Rabson A,
Martin MA. 1986. Production of acquired immunodeficiency syndrome-
associated retrovirus in human and nonhuman cells transfected with an
infectious molecular clone. J Virol 59:284–291.
64. Huang M, Orenstein JM, Martin MA, Freed EO. 1995. p6Gag is required
for particle production from full-length human immunodeficiency virus
type 1 molecular clones expressing protease. J Virol 69:6810–6818.
65. Kiernan RE, Ono A, Englund G, Freed EO. 1998. Role of matrix in an
early postentry step in the human immunodeficiency virus type 1 life
cycle. J Virol 72:4116–4126.
66. Freed EO, Martin MA. 1994. Evidence for a functional interaction be-
tween the V1/V2 and C4 domains of human immunodeficiency virus type
1 envelope glycoprotein gp120. J Virol 68:2503–2512.
67. Waheed AA, Ono A, Freed EO. 2009. Methods for the study of HIV-1
assembly. Methods Mol Biol 485:163–184. http://dx.doi.org/10.1007/978
-1-59745-170-3_12.
68. Qian K, Bori ID, Chen CH, Huang L, Lee KH. 2012. Anti-AIDS agents
90. Novel C-28 modified bevirimat analogues as potent HIV maturation
inhibitors. J Med Chem 55:8128–8136. http://dx.doi.org/10.1021
/jm301040s.
69. Qian K, Kuo RY, Chen CH, Huang L, Morris-Natschke SL, Lee KH.
2010. Anti-AIDS agents 81. Design, synthesis, and structure-activity rela-
tionship study of betulinic acid and moronic acid derivatives as potent
HIV maturation inhibitors. J Med Chem 53:3133–3141. http://dx.doi.org
/10.1021/jm901782m.
PF-46396 Structure-Activity Relationships
September 2016 Volume 90 Number 18 jvi.asm.org 8197Journal of Virology
 o
n
 August 29, 2016 by ST ANDREW
S UNIV
http://jvi.asm.org/
D
ow
nloaded from
 
